drugset / Trial / NCT00098111

Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease

NCT00098111

Phase 3 Terminated 31 enrolled Massachusetts General Hospital
RandomizedParallel-groupTriple-blind

Summary

The purpose of this study is to identify an optimal weight based dose of azathioprine that is safe and effective in the treatment of subjects with active Crohn's disease requiring treatment with corticosteroids, and for maintaining remission in those subjects.

Timeline

Start
2005-04
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azathioprine Small molecule 0.5 mg/kg
Comparator Azathioprine Small molecule 2.5 mg/kg
Comparator Azathioprine Small molecule 3.5 mg/kg

Indications